Freenome
Develops blood-based, multiomics cancer screening tests for early detection in patients and healthcare providers
Highlights
- New on EvolcAdded 2026-11-14
About Freenome
Freenome develops blood-based screening tests that combine multiomics with artificial intelligence and machine learning to detect cancer at early stages. Its first screening test targets colorectal cancer and advanced adenomas.
Founded in 2014, Freenome has about 400 employees. Its open roles include research, computational biology, software engineering, lab operations, clinical development, and commercial positions.
Product: Blood-based cancer screening tests and a multiomics platform for early detection.
Jobs at Freenome
Open roles at Freenome in the Americas (15)
United States 15. From Freenome's careers page or applicant tracking system; each role links to the employer.
- Technical Product Manager III · United States
- Strategic Account Executive (Southeast) · United States
- Strategic Account Executive (South) · United States
- Strategic Account Executive (Pacific Northwest) · United States
- Staff Software Engineer · United States
- Staff Machine Learning Scientist · Brisbane, United States
- Staff Computational Biologist · United States
- Staff Computational Biologist · Brisbane, United States
- Senior Staff Software Engineer · United States
- Senior Software Engineer II · United States
- Senior Software Engineer II · United States
- Senior Director, Real World Data (RWD) · United States
Newest 12 of 15.
More biotech & pharma companies
Frontier Medicines
Covalent small-molecule drug discovery for patients with diseases involving difficult-to-drug protein targetsNew on EvolcGatesfoundation
Non-profit developing drugs, biologics and vaccines for tuberculosis and malaria in low- and middle-income countriesGeneDx
Genetic testing and genomic diagnostics for healthcare providers, patients, health systems and biopharmaNew on EvolcGenesis Molecular AI
AI-driven drug discovery for pharmaceutical and biotech partners, using machine learning and molecular simulationNew on EvolcGilead
Develops CAR T-cell therapies and other cell therapy treatments for people with cancerGilead
Biopharmaceutical company developing and delivering therapies for serious diseases, including virology, oncology and inflammation treatments
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- FastlyHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-served-by
- Response headerx-served-by
- Response headerx-served-by
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
CRM & customer data
- HubSpotHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
- MarketoMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- OneTrustHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- GreenhouseHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.